Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

Benzinga Newsdesk www.benzinga.com Positive 92.9%

Neg 0% Neu 0% Pos 92.9%

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.